Mirum Pharmaceuticals, Inc. (MIRM) Stock Forecast
MIRM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.71 / 5 from 14 analysts
- Price target
- $153.07 average of analyst targets
- Upside to target
- +91.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.54
- 52-week range
- $64.10 – $128.57
MIRM analyst ratings
14 analystsNumber of analysts at each rating.
MIRM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
MIRM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.53 | −$0.32 | $0.05 | −950.0% | 2 |
| Current fiscal year (2026) | −$15.14 | −$15.14 | −$15.14 | −$0.47 | −3,121.3% | 1 |
| Next fiscal year (2027) | −$0.72 | −$1.24 | −$0.20 | −$15.14 | +95.2% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
MIRM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $177.8M | $170.5M | $181.7M | +33.7% | 11 |
| Current fiscal year (2026) | $696.6M | $685.0M | $706.4M | +33.6% | 13 |
| Next fiscal year (2027) | $820.0M | $750.2M | $882.5M | +17.7% | 12 |
MIRM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
MIRM revenue: reported and forecast
MIRM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.70 | −$0.70 | −$0.69 | −$0.69 | −$0.42 | −39.5% | 0 up · 0 down |
| Current fiscal year (2026) | −$16.33 | −$16.33 | −$14.24 | −$14.24 | −$15.14 | −7.3% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.19 | −$0.35 | −$0.35 | −$0.35 | −$0.72 | +283.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
MIRM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; MIRM beat in 4 of 12.
What analysts expect from MIRM
14 analysts cover Mirum Pharmaceuticals; their consensus rating is strong buy (4.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $153.07, 91.0% above the latest close of $80.14. Analysts expect earnings of −$15.14 per share for 2026, −3,121.3% from a year earlier. For 2027 the average estimate is −$0.72 per share on revenue of $820.0 million. Mirum Pharmaceuticals beat the EPS estimate in 4 of the last 12 quarters.
Related: MIRM income statement, MIRM key metrics, MIRM chart. See the MIRM stock overview for the latest quote and news.
MIRM forecast FAQ
What is Mirum Pharmaceuticals's price target?
The average analyst price target for Mirum Pharmaceuticals is $153.07, 91.0% above the latest close of $80.14.
Is Mirum Pharmaceuticals a buy, hold or sell?
Of 14 analysts covering Mirum Pharmaceuticals, 10 rate it a strong buy, 4 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Mirum Pharmaceuticals's EPS forecast?
Analysts forecast −$15.14 per share for 2026 (range −$15.14 to −$15.14); for 2027 the estimate is −$0.72.
What is Mirum Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $696.6 million, growth of 33.6%; for 2027 it is $820.0 million.
When does Mirum Pharmaceuticals report earnings?
Mirum Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-0.54.
Does Mirum Pharmaceuticals usually beat earnings estimates?
Mirum Pharmaceuticals reported EPS at or above the analyst estimate in 4 of the last 12 quarters.